In this scenario the insulin analogues could act either as a tumor initiator by transforming benign or (pre)neoplastic cells, which often express increased levels of IRA and IGF1R [15], or as a tumor promoter by stimulating the increased growth potential of these cells. This evidence concerns the gene IGF1R and neoplasm.